Akmansu M, Dîrîcan B, Oztürk B, Egehan I, Subaşi M, Or M
Department of Radiation Oncology, Gazi University Medical Faculty, Ankara, Turkey.
Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):923-7. doi: 10.1016/s0360-3016(97)00859-6.
This study was performed to determine the toxicity and efficacy of external-beam radiotherapy in patients with age-related subfoveal neovascularization.
Between January 1996 and September 1996, 25 patients with a mean age of 70.5 (60-84) years were enrolled. All patients underwent fluorescein angiographic evaluation and documentation of their neovascular disease prior to irradiation. A total of 25 patients were treated with a total dose of 12 Gy in 6 fractions over 8 days. We used a lens-sparing technique and patients were treated with a single lateral 6-MV photon beam. To assess the risk of radiation carcinogenesis after treatment of age-related subfoveal neovascularization, we estimated the effective dose for a standard patient on the basis of tissue-weighting factors as defined by the International Commission on Radiological Protection (ICRP). The calculations were made with TLD on a male randophantom. The lens dose was found to be 0.217 Gy per fraction.
No significant acute morbidity was noted. Visual acuity was maintained or improved in 76% and 80% of treated patients at their 1- and 3-month follow-up examinations, respectively. On angiographic imaging, there was stabilization of subfoveal neovascular membranes in 23 patients (92%) at 3 months after irradiation.
Our observations on these 25 patients in this study indicate that many patients will have improved or stable vision after radiotherapy treatment with low-dose irradiation.
本研究旨在确定外照射放疗对年龄相关性黄斑下新生血管形成患者的毒性和疗效。
1996年1月至1996年9月,纳入了25例平均年龄为70.5岁(60 - 84岁)的患者。所有患者在放疗前均接受了荧光素血管造影评估并记录其新生血管疾病情况。总共25例患者在8天内分6次接受了总量为12 Gy的治疗。我们采用了晶状体保护技术,患者接受单侧6兆伏光子束治疗。为了评估年龄相关性黄斑下新生血管形成治疗后发生放射性致癌的风险,我们根据国际放射防护委员会(ICRP)定义的组织权重因子估算了标准患者的有效剂量。计算是在男性兰多人体模型上用热释光剂量计进行的。发现晶状体剂量为每次分割0.217 Gy。
未观察到明显的急性并发症。在1个月和3个月的随访检查中,分别有76%和80%的治疗患者视力得以维持或改善。在血管造影成像上,照射后3个月时23例患者(92%)的黄斑下新生血管膜稳定。
我们对本研究中这25例患者的观察表明,许多患者在低剂量放疗后视力会得到改善或保持稳定。